We read with interest the Article by Dean Fennell and colleagues1 reporting the results of the randomised, phase 3 CONFIRM mesothelioma trial, which assessed the role of nivolumab in the second-line setting. Since our first attempt to use the anti-CTLA-4 tremelimumab as second-line treatment for patients with mesothelioma in 2013,2 several trials have further explored the use of immune checkpoint inhibitors in this setting. Notwithstanding, the gain of survival in the intervention groups remains very small.3 The CONFIRM trial does not provide clarity on this issue, given the investigators’ choice to compare immunotherapy versus placebo. The authors reported a median overall survival of 10·2 months (95% CI 8·5–12·1) in the nivolumab group versus 6·9 months (5·0–8·0) in the placebo group (hazard ratio 0·69 [95% CI 0·52–0·91]; p=0·0090).
CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma?
Pentimalli, FrancescaWriting – Original Draft Preparation
;
2022-01-01
Abstract
We read with interest the Article by Dean Fennell and colleagues1 reporting the results of the randomised, phase 3 CONFIRM mesothelioma trial, which assessed the role of nivolumab in the second-line setting. Since our first attempt to use the anti-CTLA-4 tremelimumab as second-line treatment for patients with mesothelioma in 2013,2 several trials have further explored the use of immune checkpoint inhibitors in this setting. Notwithstanding, the gain of survival in the intervention groups remains very small.3 The CONFIRM trial does not provide clarity on this issue, given the investigators’ choice to compare immunotherapy versus placebo. The authors reported a median overall survival of 10·2 months (95% CI 8·5–12·1) in the nivolumab group versus 6·9 months (5·0–8·0) in the placebo group (hazard ratio 0·69 [95% CI 0·52–0·91]; p=0·0090).I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
